華潤醫藥(03320.HK):華潤醫藥商業建議增加註冊資本
格隆匯12月29日丨華潤醫藥(03320.HK)發佈公吿,建議認購事項的投標程序已於2023年12月25日屆滿,及於2023年12月28日,華潤醫藥商業與北京醫藥、華潤醫藥投資及投資者認購人訂立認購協議,據此,華潤醫藥商業已同意將其註冊資本由人民幣150億元增加約人民幣46.465億元至約人民幣196.465億元,其中(i)投資者認購人已同意認購所增加的註冊資本合共約人民幣39.043億元,代價總額為人民幣52.6億元,及(ii)北京醫藥及華潤醫藥投資(作為現有股東認購人)已同意認購所增加的註冊資本合共約人民幣7.423億元,代價總額為人民幣10億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.